Evolus: Pay

Evolus paid its 5 named executives $14.6M in total in FY2025 (Dec). CEO David Moatazedi was paid $6.4M of that.

Pay$100 in the stock at the end of FY21 → $102
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

David MoatazediPresident and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Tatjana MitchellChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
3 years
Sandra BeaverFormer Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Rui Avelar, M.D.Chief Medical Officer and Head of Research and Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Tomoko Yamagishi-DresslerFormer Chief Marketing Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $7.2M. The CEO of Evolus was paid $6.4M, 11% below the median.

  1. 1GLAUKOS
  2. 2Axogen
  3. 3Staar Surgical
  4. 4Arcutis Biotherapeutics
  5. 5Mimedx Group
  6. 6Tarsus Pharmaceuticals
  7. 7Evolus
  8. 8Establishment Labs Holdings
  9. 9Agenus Inc.Not disclosed
  10. 10Anika Therapeutics, Inc.Not disclosed
  11. 11Bioventus Inc.Not disclosed
  12. 12Coherus Oncology, Inc.Not disclosed
  13. 13HarrowNot disclosed
  14. 14InMode Ltd.Not disclosed
  15. 15Olaplex Holdings, Inc.Not disclosed
  16. 16Revance Therapeutics, Inc.Not disclosed
  17. 17RxSightNot disclosed
  18. 18The Beauty Health CompanyNot disclosed
  19. 19VericelNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.